CYAD — Celyad Oncology SA Cashflow Statement
0.000.00%
Last trade - 00:00- €13.43m
- €11.72m
- €0.02m
Annual cashflow statement for Celyad Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.5 | -40.9 | -8.45 | -5.82 | 0.83 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -3.08 | 13.3 | -1.1 | -0.147 | -2.01 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.43 | -1.84 | -6.45 | -0.159 | -5.89 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -26.6 | -28 | -15.2 | -5.68 | -6.9 |
| Capital Expenditures | -0.393 | -0.123 | -0.934 | -0.118 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.267 | 7.33 | 1.34 | 0.015 | 3.01 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.126 | 7.2 | 0.407 | -0.103 | 3.01 |
| Financing Cash Flow Items | 4.09 | 4.26 | 0.01 | 3.15 | 0.555 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39.5 | 3.24 | 9.36 | 2.98 | 1.39 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 12.8 | -17.6 | -5.44 | -2.8 | -2.49 |